Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT06073093

Public ClinicalTrials.gov record NCT06073093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study treatment includes investigational medicinal product (IMP: SAR441566 or placebo) added-on to a background therapy of MTX. Study details include a run-in period (4 to 6 weeks) before randomization to determine eligibility, a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number of scheduled study visits will be 8.

Study identification

NCT ID
NCT06073093
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
264 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2023
Primary completion
Jun 17, 2025
Completion
Jul 1, 2025
Last update posted
Jul 10, 2025

2023 – 2025

United States locations

U.S. sites
17
U.S. states
8
U.S. cities
17
Facility City State ZIP Site status
Amicis Research Center - Northridge - Nordhoff Street- Site Number : 8400023 Northridge California 91324
Inland Rheumatology & Osteoporosis Medical Group- Site Number : 8400004 Upland California 91786
UF Health Deerwood Park- Site Number : 8400020 Jacksonville Florida 32256
Life Clinical Trials- Site Number : 8400028 Margate Florida 33063
Future Care Solution - Miami- Site Number : 8400019 Miami Florida 33142
Innovia Research Center, Inc- Site Number : 8400026 Miramar Florida 33027
Integral Rheumatology and Immunology Specialists- Site Number : 8400010 Plantation Florida 33324
Clinical Research of West Florida - Tampa - North Howard Avenue- Site Number : 8400017 Tampa Florida 33606
Inspire Santa Fe Medical Group- Site Number : 8400029 Santa Fe New Mexico 87505
Arthritis and Osteoporosis Consultants of the Carolinas- Site Number : 8400012 Charlotte North Carolina 28207
Carolina Specialty Care- Site Number : 8400007 Statesville North Carolina 28625
Altoona Center for Clinical Research- Site Number : 8400002 Duncansville Pennsylvania 16635
Low Country Rheumatology- Site Number : 8400018 Summerville South Carolina 29486
American Indian Clinical Trials Research Network - Rapid City- Site Number : 8400022 Rapid City South Dakota 57701
Prolato Clinical Research Center- Site Number : 8400021 Houston Texas 77054
AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400031 Irving Texas 75039
Perceptive Pharma Research- Site Number : 8400009 Richmond Texas 77407

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06073093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 10, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06073093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →